Dex Pharma Reta Max 50mg/3mL Pen

Key Benefits

• Maximized Fat Loss: Significant reduction in visceral and subcutaneous fat via enhanced metabolic rate.
• Blood Sugar Regulation: Drastically improves insulin sensitivity and glucose control.
• Appetite Suppression: Delays gastric emptying and signals fullness to the brain to reduce caloric intake.
• Liver Health: Specifically researched for its ability to reduce liver fat more effectively than previous generations of GLP-1s.

Dosage Guide (50mg/3ml Pen)

This pen is highly concentrated. Following the official protocol:

• Step 1 (Starting): 1–2 mg once weekly for Weeks 1–4.
• Step 2 (Escalation): 2–3 mg weekly only if Step 1 was comfortable.
• Step 3 (Therapeutic): 3–4 mg weekly. Most users find their long-term maintenance dose in this range.
• Step 4 (Advanced): 4–6 mg weekly. Advance only if you have no side effects and your results have stalled.

Tips for Success

• Titrate Slowly: Don't rush to increase the dose; the "right" dose is the lowest one that still provides results.
• Hydration: Retatrutide can be dehydrating and may cause mild nausea; drink plenty of water and electrolytes.
• Liver Support: It is particularly effective for those looking to improve liver markers alongside fat loss.

1. What makes Retatrutide different from Ozempic or Mounjaro? Retatrutide is a "triple agonist." While Ozempic hits one receptor and Mounjaro hits two, Retatrutide targets three (GLP-1, GIP, and Glucagon), leading to potentially higher metabolic rates and fat loss.

2. How does the Glucagon receptor help with weight loss? The Glucagon component increases energy expenditure and targets fat specifically in the liver, effectively "revving" your metabolic engine rather than just suppressed appetite.

3. What is the starting dose? Research protocols recommend starting at 1-2mg once per week for at least four weeks to allow the body to adjust.

4. How do I calculate the dose with a 50mg/3ml pen? With 50mg in 3ml, the concentration is approx 1.67mg per 0.1ml (10 units). Always double-check your pen's specific click-chart for exact milligram-to-click ratios.

5. How often do I take it? Retatrutide is administered once weekly, on the same day each week.

6. What are the most common side effects? Nausea, mild diarrhea, and fatigue are the most common. Because of the Glucagon component, some users also report a slightly elevated resting heart rate.

7. Do I have to titrate (increase) the dose every month? No. You should stay at the lowest effective dose as long as you are seeing results. Only move up if your progress stalls and side effects are non-existent.

8. Can I switch from Tirzepatide to Retatrutide? Yes, though most researchers suggest a "washout" period or starting at a lower Retatrutide dose to gauge the body's response to the third receptor.

9. How long does a 50mg pen last? Depending on your dose, it can last a long time. At a 2mg weekly dose, a 50mg pen technically contains 25 weeks of medication; however, shelf life after first use is generally 60 days.

10. Does it need to be refrigerated? Yes. To maintain the structural integrity of the triple-agonist peptide, the pen must be stored in the refrigerator.

11. Will it cause muscle loss? Any rapid weight loss can include muscle. It is critical to prioritize high protein intake (1.6g/kg) and resistance training while using this peptide.

12. When is the best time to inject? Most users prefer evening injections to "sleep through" any immediate nausea, though the specific time of day does not affect fat loss results.

13. Does it help with fatty liver? Yes, clinical data suggests Retatrutide is exceptionally effective at clearing liver fat due to its Glucagon receptor activity.

14. What should I do if I feel severe nausea? Hold your current dose (do not escalate) and focus on smaller, lower-fat meals. Ensure you are well-hydrated with electrolytes.

15. Can I drink alcohol on Retatrutide? It is generally discouraged, especially during the titration phase, as alcohol can worsen GI side effects and blood sugar fluctuations.

Retatrutide, also known as LY3437943, is an investigational once-weekly peptide currently being studied for weight management, type 2 diabetes, metabolic health, and liver-fat reduction. It is described as a triple hormone receptor agonist, meaning it activates the GIP, GLP-1, and glucagon receptors. This gives it a different mechanism from semaglutide, which mainly targets GLP-1, and tirzepatide, which targets GIP and GLP-1. Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist.

Retatrutide is currently being researched and is not yet registered as an approved treatment, but early clinical studies and recent Phase 3 topline results have shown promising potential.

1. Phase 2 obesity study — significant body-weight reduction

A Phase 2 study published in the New England Journal of Medicine studied retatrutide in adults with obesity or overweight. The trial found that retatrutide produced substantial reductions in body weight over 48 weeks. Lilly and the published trial reported strong average weight-loss results, with higher-dose groups showing the largest reductions. The study also reported that the most common side effects were gastrointestinal, such as nausea, diarrhoea, and vomiting.

Original article:

https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

2. Liver-fat / MASLD research — large reductions in liver fat

A Nature Medicine publication looked at retatrutide’s effect on liver fat in participants with metabolic dysfunction-associated steatotic liver disease, also known as MASLD or fatty liver disease. The study reported very large reductions in liver fat, with the 12 mg group showing an 86% relative liver-fat reduction at 48 weeks. This has made retatrutide one of the more closely watched compounds in metabolic and liver-health research.

Original article:

https://www.nature.com/articles/s41591-024-03018-2

3. Type 2 diabetes Phase 3 topline results — improved A1C and weight

In March 2026, Lilly announced Phase 3 results from TRANSCEND-T2D-1, a study of retatrutide in people with type 2 diabetes. Lilly reported that retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks, and that participants taking the 12 mg dose lost an average of 36.6 lb / 16.8% body weight. These are manufacturer-reported topline results and should be interpreted as part of the ongoing clinical development programme.

Original Lilly release:

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant

ClinicalTrials.gov study listing:

https://clinicaltrials.gov/study/NCT06297603

4. Obesity and knee osteoarthritis Phase 3 study — weight loss and pain improvement

Lilly reported Phase 3 results from TRIUMPH-4, a trial studying retatrutide in people with obesity and knee osteoarthritis. In this study, participants taking the 12 mg dose lost an average of 28.7% of body weight at 68 weeks, compared with 2.1% in the placebo group. Lilly also reported improvement in knee-pain outcomes, which may be linked partly to the substantial weight reduction.

Original Lilly release:

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

ClinicalTrials.gov study listing:

https://clinicaltrials.gov/study/NCT05931367

5. Lilly overview — what retatrutide is

Lilly’s own educational page describes retatrutide as an investigational once-weekly triple hormone receptor agonist that activates receptors for GIP, GLP-1, and glucagon. Lilly also notes that retatrutide is being studied in clinical trials and is not an approved medicine at this stage.

Lilly overview page:

https://www.lilly.com/news/stories/what-to-know-about-retatrutide

Quick Research Summary

Current research suggests that retatrutide may offer strong potential in weight-management and metabolic-health research because of its triple-action activity on GIP, GLP-1, and glucagon receptors. Published Phase 2 studies have shown substantial body-weight reduction and major liver-fat reductions, while recent Phase 3 topline data from Lilly has reported strong A1C and weight-loss outcomes. However, retatrutide remains investigational, and full long-term safety, regulatory review, and approval decisions are still ongoing.

Important: Retatrutide is currently being researched and is not yet registered as an approved treatment. This information is provided for educational and research-reference purposes only and should not be taken as medical advice. Customers should consult a qualified healthcare professional before making any health-related decisions.